Zhejiang Jolly Pharmaceutical Co.,LTD: history, ownership, mission, how it works & makes money

Founded in 1995 and listed on the Shenzhen Stock Exchange as 300181, Zhejiang Jolly Pharmaceutical Co., Ltd. has evolved into a vertically integrated player blending traditional Chinese medicine and modern pharmaceuticals, reporting a 2024 revenue of 2.58 billion yuan-a sharp 32.71% year‑over‑year increase-while delivering a net income of 507.77 million yuan and declaring a shareholder cash dividend of 6.00 yuan per 10 shares for 2024; with a market capitalization near 12.79 billion yuan, a net cash position (cash and equivalents of 804.7 million yuan versus total debt of 426.2 million yuan), plans to raise up to 1.6 billion yuan via bond issuance, and a digital workshop for solid preparations slated to be operational by end‑2025, Jolly's mix of flagship TCM products (Wuling capsule, Lingze tablet, Bailing tablet), modern chemical injections, direct medical service involvement through Deqing No.3 People's Hospital, and capital‑raising initiatives spotlight how the company scales production, funds R&D and expansion, and positions itself for further market penetration

Zhejiang Jolly Pharmaceutical Co.,LTD (300181.SZ): Intro

• Founded: 1995 - began as a TCM-focused manufacturer.
• IPO: Listed on Shenzhen Stock Exchange in 2011 (300181.SZ).
• Business scope: TCM preparations, chemical pharmaceuticals, health products, contract manufacturing (CMO) services and digital manufacturing.

• 2024 revenue: 2.58 billion yuan (up 32.71% year-over-year).
• 2024 cash dividend: approved May 2025 - 6.00 yuan per 10 shares.
• 2025 financing plan: authorized to raise up to 1.6 billion yuan via bond issuance to finance projects and capacity expansion.

• Product sales: prescription and OTC TCM and chemical drugs across hospitals, pharmacies and e-commerce channels.
• Contract manufacturing: third-party production services leveraging GMP-certified facilities.
• Specialty products: proprietary TCM formulas and patented preparations with higher margins.
• Service & digitalization: process optimization and smart production boosting yield and reducing cost per unit.

• Digital workshop: a digitalized solid preparation workshop is slated to be operational by end-2025 to raise automation, batch traceability and throughput.
• Use of bond proceeds: project construction, equipment upgrades, and working capital to support accelerated product commercialization.

• Dual focus on TCM and modern pharmaceuticals provides product diversification and resilience.
• Public listing enables scalable capital allocation (dividends and bond financing illustrated).
• Investment in digital manufacturing targets lower unit costs and faster time-to-market.
• Established distribution channels across hospitals, retail pharmacies and online platforms.

Zhejiang Jolly Pharmaceutical Co.,LTD (300181.SZ): History

• Listed on the Shenzhen Stock Exchange (300181.SZ), attracting a mix of institutional and retail investors.
• Market capitalization: ≈12.79 billion yuan (as of December 11, 2025).
• Shareholder distributions: 2024 cash dividend approved in May 2025 - 6.00 yuan per 10 shares.
• Active capital-raising: proposed bond issuance up to 1.6 billion yuan (Dec 2025) to fund projects and growth.

• Shareholder base: diversified-domestic institutions, funds, and individual investors.
• Corporate governance: board-led strategic investments in manufacturing automation and R&D.

• Mission: develop reliable, affordable pharmaceuticals while upgrading manufacturing through digitalization.
• R&D & product mix: emphasis on solid dosage forms and selected APIs to serve hospitals, distributors and retail channels.
• Manufacturing: transitioning to automated digital workshops to raise yield, traceability and regulatory compliance.

• Product sales: primary revenue from sales of finished pharmaceuticals (hospital tenders, distributors, retail pharmacies).
• API and intermediates: B2B sales to other pharmaceutical manufacturers supplement margins.
• Contract manufacturing and licensing: selective OEM/ODM contracts and formulation licensing add recurring income streams.
• Capital deployment: using net cash and bond proceeds to expand capacity (digital workshop), fund R&D and support pipeline commercialization.

• Net cash position (cash 804.7M vs debt 426.2M) provides cushion for R&D and M&A.
• Bond issuance (up to 1.6B) earmarked for capacity, digitalization and project financing to accelerate revenue growth.
• Dividend policy signals shareholder-friendly returns while pursuing expansion.

Zhejiang Jolly Pharmaceutical Co.,LTD (300181.SZ): Ownership Structure

• Flagship products: Wuling capsule, Lingze tablet, Bailing tablet - core revenue drivers rooted in traditional formulas adapted to modern production.
• Quality & efficiency initiatives: large-scale investment in a digital workshop for solid preparations, targeted to be operational by end-2025 to improve batch traceability, yield and GMP compliance.
• Healthcare integration: participation in medical services through Deqing No.3 People's Hospital, linking manufacturing expertise with direct patient care and service revenue streams.

• Capital allocation & shareholder focus: the 2024 cash dividend and 2025 bond plan signal a dual emphasis on returning capital and funding scalability (production digitalization, R&D, and integration with medical services).
• Revenue model highlights: product sales of TCM preparations, margin enhancement from tech-driven production, and supplementary income from medical services operations.

Zhejiang Jolly Pharmaceutical Co.,LTD (300181.SZ): Mission and Values

• Core business lines: TCM finished products (capsules, tablets, granules), modern chemical injections, API supply, and medical services via hospital participation.
• Flagship TCM brands: Wuling capsule, Lingze tablet, Bailing tablet.
• Key modern pharmaceutical products: azithromycin injection, clindamycin phosphate injection (and other sterile injections).

• Research & Development - in-house formulation development for TCM and sterile injections; clinical and quality control capabilities to support registration and lifecycle management.
• Manufacturing - vertically integrated plants for solid oral dosage forms and sterile injections; quality systems aligned with national GMP standards.
• Distribution & Marketing - national sales network for hospital and retail channels; brand marketing for legacy TCM products combined with hospital procurement for injections.
• Medical Services - equity/operational participation in Deqing No.3 People's Hospital to link product usage, clinical feedback and local patient access.

• Product sales - primary revenue from TCM finished goods and modern injectable medicines sold to hospitals, distributors and pharmacies.
• Hospital operations - clinical service revenue and channel synergies from Deqing No.3 People's Hospital participation.
• Contract manufacturing and API sales - third-party manufacturing and raw material supply opportunities complement branded sales.
• Licensing and partnership income - R&D collaborations and distribution agreements in domestic markets.

• Digital production - a digital workshop for solid pharmaceutical preparations is targeted to be operational by end-2025 to improve yield, reduce labor intensity and scale capacity.
• Capital raising - active capital-market activities (including the planned Dec 2025 bond issuance) to finance manufacturing upgrades, R&D and potential M&A.
• Healthcare integration - leveraging Deqing No.3 People's Hospital for real-world evidence, clinical adoption of products and downstream services.

• Product mix - combination of high-margin TCM branded products and stable-volume sterile injections sold into hospital procurement channels.
• Quality & compliance - GMP-standard facilities and regulated registration pathways for injections support market access and pricing resilience.
• Scale & distribution - national sales reach for legacy TCM brands, supplemented by hospital channel relationships for modern injections.

Zhejiang Jolly Pharmaceutical Co.,LTD (300181.SZ): How It Works

• R&D: development of TCM formulations and modern drug candidates, leveraging proprietary production techniques.
• Manufacturing: GMP-compliant production lines for TCM products, tablets, capsules and sterile preparations.
• Distribution & Sales: national sales network and partnerships with distributors and hospitals for product placement.
• Healthcare Services: participation in Deqing No.3 People's Hospital to connect products with clinical application and patient care.

• Product sales - TCM and modern pharmaceuticals sold through hospital channels, pharmacies and distributors.
• Clinical and hospital-related revenue - synergies from hospital participation (Deqing No.3 People's Hospital) supporting product adoption and service income.
• Licensing and technology transfer - selected out-licensing or partnerships for specific formulations or manufacturing processes.

• Operating cash flow and retained earnings fund R&D and manufacturing upgrades.
• Planned bond issuance (up to 1.6 billion CNY in Dec 2025) to finance capacity expansion, working capital and strategic projects.
• Dividend policy: cash dividend of 6.00 CNY per 10 shares for 2024 reflects return-of-capital practice while balancing reinvestment needs.

• Dual-focus product portfolio (TCM + modern drugs) diversifies revenue streams and market reach.
• Integration with Deqing No.3 People's Hospital helps clinical validation and adoption, shortening commercialization cycles.
• Robust margin (≈19.7% in 2024) indicates disciplined cost control across manufacturing and supply chain.

Zhejiang Jolly Pharmaceutical Co.,LTD (300181.SZ): How It Makes Money

• Product sales: branded TCM finished dosages (capsules, tablets, granules) sold through hospital channels, retail pharmacies, and distributors.
• Contract manufacturing and OEM: third-party production capacity for other pharmaceutical firms and private labels.
• Medical services and hospital integration: revenue from Deqing No.3 People's Hospital operations and related clinical partnerships.
• Government and institutional procurement: tenders and bulk purchases for public healthcare institutions.
• Financial operations and capital market activities: bond issuance and other financing to support expansion and R&D.